Kadmon Nabs Dyax’ MMP-14 Inhibitor mAb

Kadmon negotiated an exclusive worldwide license to develop Dyax’s fully human monoclonal antibody matrix metalloproteinase 14 (MMP14) inhibitor DX-2400, which is currently undergoing IND-enabling studies.

Espero, Armetheon Plan Merger into Commercial-Stage Cardiovascular BioPharma

New biopharma will start out with marketed angina drug, pivotal-stage anticoagulant and Phase II-stage antiarrhythmic

GSK, Zymeworks Launch Up-to-$440M+ Antibody Collaboration

Companies to design and commercialize new Fc-engineered monoclonal and bi-specific antibody drugs using Zymeworks' EEFECT platform

TaiGen Acquires Global Rights to Warner Chilcott’s Late-Stage Antibiotic

Taiwanese firm projects completing Phase III trials with oral nemonoxacin in China and Taiwan during 2012.

Roivant’s Newest Company to Develop Ligand’s Diabetes Candidate LGD-6972

Ligand Pharmaceuticals could generate up to $533.8 million+ through partnership with Roivant, which will develop the Phase III-ready glucagon receptor antagonist LGD-6972

FDA Rejects NDAs for Cempra Bacterial Pneumonia Candidate Solithromycin

Agency says additional clinical safety information and the satisfactory resolution of manufacturing facility inspection deficiencies needed before the NDAs can be approved

Antibiotic-Antigen Conjugates Bring Immunotherapy to Deadly Bacteria

Immunobiotics, small molecules that combine immunostimulatory agents and antbiotics, decrease the number of live gram-negative bacteria in human serum.

Nanosponge Vaccine Breaks through Safety/Efficacy Tradeoff

A nanoparticle-based toxin-detainment strategy is used to safely deliver non-disrupted pore-forming toxins for immune processing.

Celgene Launches $1B Immunotherapy Collaboration with Juno

Companies will develop cancer and autoimmune disease treatments based on CAR-T and T cell receptor technologies over a 10-year period

Recently Featured

Stay Connected

Scroll Up